Advertisement

Diabetic Neuropathy

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Endocrinology and Metabolism Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Vinik A.I.
        • Mitchell B.D.
        • Leichter S.B.
        • et al.
        Epidemiology of the complications of diabetes.
        in: Leslie R.D. Robbins D.C. Diabetes: clinical science in practice. Cambridge University Press, Cambridge (United Kingdom)1995: 221-287
        • Holzer S.E.
        • Camerota A.
        • Martens L.
        • et al.
        Costs and duration of care for lower extremity ulcers in patients with diabetes.
        Clin Ther. 1998; 20: 169-181
        • Caputo G.M.
        • Cavanagh P.R.
        • Ulbrecht J.S.
        • et al.
        Assessment and management of foot disease in patients with diabetes.
        N Engl J Med. 1994; 331: 854-860
        • Herman W.H.
        • Kennedy L.
        Underdiagnosis of peripheral neuropathy in type 2 diabetes.
        Diabetes Care. 2005; 28: 1480-1481
        • Young M.J.
        • Boulton A.J.
        • MacLeod A.F.
        • et al.
        A multicenter study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population.
        Diabetologia. 1993; 36: 150-154
        • Dyck P.J.
        • Kratz K.M.
        • Karnes J.L.
        • et al.
        The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study.
        Neurology. 1993; 43: 817-824
        • Vinik A.
        Diabetic neuropathy: pathogenesis and therapy.
        Am J Med. 1999; 107: 17S-26S
        • Armstrong D.G.
        • Lavery L.A.
        • Harkless L.B.
        Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation.
        Diabetes Care. 1998; 21: 855-859
        • Vinik E.J.
        • Hayes R.P.
        • Oglesby A.
        • et al.
        The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy.
        Diabetes Technol Ther. 2005; 7: 497-508
        • Levitt N.S.
        • Stansberry K.B.
        • Wychanck S.
        • et al.
        Natural progression of autonomic neuropathy and autonomic function tests in a cohort of IDDM.
        Diabetes Care. 1996; 19: 751-754
        • Rathmann W.
        • Ziegler D.
        • Jahnke M.
        • et al.
        Mortality in diabetic patients with cardiovascular autonomic neuropathy.
        Diabet Med. 1993; 10: 820-824
        • Vinik A.
        • Ullal J.
        • Parson H.K.
        • et al.
        Diabetic neuropathies: clinical manifestations and current treatment options.
        Nat Clin Pract Endocrinol Metab. 2006; 2: 269-281
        • Sadosky A.
        • McDermott A.M.
        • Brandenburg N.A.
        • et al.
        A review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions.
        Pain Pract. 2008; 8: 45-56
        • Tesfaye S.
        • Boulton A.J.
        • Dyck P.J.
        • et al.
        Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments.
        Diabetes Care. 2010; 33: 2285-2293
        • Ziegler D.
        Painful diabetic neuropathy: treatment and future aspects.
        Diabetes Metab Res Rev. 2008; 24: S52-S57
        • Boulton A.J.
        • Malik R.A.
        • Arezzo J.C.
        • et al.
        Diabetic somatic neuropathies.
        Diabetes Care. 2004; 27: 1458-1486
        • Vinik A.I.
        • Ziegler D.
        Diabetic cardiovascular autonomic neuropathy.
        Circulation. 2007; 115: 387-397
        • Vinik A.I.
        • Maser R.E.
        • Ziegler D.
        Neuropathy: the crystal ball for cardiovascular disease?.
        Diabetes Care. 2010; 33: 1688-1690
        • Vinik A.I.
        • Maser R.E.
        • Ziegler D.
        Autonomic imbalance: prophet of doom or scope for hope?.
        Diabet Med. 2011; 28: 643-651
        • Dieleman J.P.
        • Kerklaan J.
        • Huygen F.J.
        • et al.
        Incidence rates and treatment of neuropathic pain conditions in the general population.
        Pain. 2008; 137: 681-688
        • Cornblath D.R.
        • Vinik A.
        • Feldman E.
        • et al.
        Surgical decompression for diabetic sensorimotor polyneuropathy.
        Diabetes Care. 2007; 30: 421-422
        • Ziegler D.
        • Rathmann W.
        • Dickhaus T.
        • et al.
        Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3.
        Diabetes Care. 2008; 31: 464-469
        • Smith A.G.
        • Russell J.
        • Feldman E.L.
        • et al.
        Lifestyle intervention for pre-diabetic neuropathy.
        Diabetes Care. 2006; 29: 1294-1299
        • Ziegler D.
        • Rathmann W.
        • Meisinger C.
        • et al.
        Prevalence and risk factors of neuropathic pain in survivors of myocardial infarction with pre-diabetes and diabetes. The KORA Myocardial Infarction Registry.
        Eur J Pain. 2009; 13: 582-587
        • Ziegler D.
        • Rathmann W.
        • Dickhaus T.
        • et al.
        Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3.
        Pain Med. 2009; 10: 393-400
        • Vinik A.I.
        • Holland M.T.
        • LeBeau J.M.
        • et al.
        Diabetic neuropathies.
        Diabetes Care. 1992; 15: 1926-1975
        • Vinik A.
        • Mehrabyan A.
        Diabetic neuropathies.
        Med Clin North Am. 2004; 88: 947-999
        • Vinik A.
        • Mehrabyan A.
        • Colen L.
        • et al.
        Focal entrapment neuropathies in diabetes.
        Diabetes Care. 2004; 27: 1783-1788
        • Wilbourn A.J.
        Diabetic entrapment and compression neuropathies.
        in: Dyck P.J. Thomas P.K. Diabetic neuropathy. WB Saunders, Toronto1999: 481-508
        • Watanabe K.
        • Hagura R.
        • Akanuma Y.
        • et al.
        Characteristics of cranial nerve palsies in diabetic patients.
        Diabetes Res Clin Pract. 1990; 10: 19-27
        • Perkins B.
        • Olaleye D.
        • Bril V.
        Carpal tunnel syndrome in patients with diabetic polyneuropathy.
        Diabetes Care. 2002; 25: 565-569
        • Llewelyn J.G.
        • Thomas P.K.
        • King R.H.
        Epineurial microvasculitis in proximal diabetic neuropathy.
        J Neurol. 1998; 245: 159-165
        • Vinik A.I.
        • Pittenger G.L.
        • Milicevic Z.
        • et al.
        Autoimmune mechanisms in the pathogenesis of diabetic neuropathy.
        in: Eisenbarth R.G. Molecular mechanisms of endocrine and organ specific autoimmunity. 1st edition. Landes Company, Georgetown, Texas1998: 217-251
        • Steck A.J.
        • Kappos L.
        Gangliosides and autoimmune neuropathies: classification and clinical aspects of autoimmune neuropathies.
        J Neurol Neurosurg Psychiatry. 1994; 57: 26-28
        • Ayyar D.R.
        • Sharma K.R.
        Chronic inflammatory demyelinating polyradiculoneuropathy in diabetes mellitus.
        Curr Diab Rep. 2004; 4: 409-412
        • Krendel D.A.
        • Costigan D.A.
        • Hopkins L.C.
        Successful treatment of neuropathies in patients with diabetes mellitus.
        Arch Neurol. 1995; 52: 1053-1061
        • Barada A.
        • Reljanovic M.
        • Milicevic Z.
        • et al.
        Proximal diabetic neuropathy—response to immunotherapy.
        Diabetes. 1999; 48: A148
        • Boulton A.J.
        • Malik R.A.
        Diabetic neuropathy.
        Med Clin North Am. 1998; 82: 909-929
        • Thomas P.K.
        Classification, differential diagnosis, and staging of diabetic peripheral neuropathy.
        Diabetes. 1997; 46: S54-S57
        • Oyibo S.O.
        • Prasad Y.D.
        • Jackson N.J.
        • et al.
        The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study.
        Diabet Med. 2002; 19: 870-873
        • Sinnreich M.
        • Taylor B.V.
        • Dyck P.J.
        Diabetic neuropathies. Classification, clinical features, and pathophysiological basis.
        Neurologist. 2005; 11: 63-79
        • Vinik A.
        Management of the patient with neuropathic pain.
        in: Wartofsky L. Endocrine Society, 2012: 177-194 (J Clin Endocrinol Metab 2010;95:4802–11 [reprint])
        • Archer A.G.
        • Watkins P.J.
        • Thomas P.K.
        • et al.
        The natural history of acute painful neuropathy in diabetes mellitus.
        J Neurol Neurosurg Psychiatry. 1983; 46: 491-499
        • Partanen J.
        • Niskanen L.
        • Lehtinen J.
        • et al.
        Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus.
        N Engl J Med. 1995; 333: 89-94
        • Harris M.
        • Eastman R.
        • Cowie C.
        Symptoms of sensory neuropathy in adults with NIDDM in the U.S. population.
        Diabetes Care. 1993; 16: 1446-1452
        • Singleton J.R.
        • Smith A.G.
        • Bromberg M.B.
        Painful sensory polyneuropathy associated with impaired glucose tolerance.
        Muscle Nerve. 2001; 24: 1225-1228
        • Singleton J.R.
        • Smith A.G.
        • Bromberg M.B.
        Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy.
        Diabetes Care. 2001; 24: 1448-1453
        • Novella S.P.
        • Inzucchi S.E.
        • Goldstein J.M.
        The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy.
        Muscle Nerve. 2001; 24: 1229-1231
        • Sumner C.
        • Sheth S.
        • Griffin J.
        • et al.
        The spectrum of neuropathy in diabetes and impaired glucose tolerance.
        Neurology. 2003; 60: 108-111
        • Pittenger G.L.
        • Ray M.
        • Burcus N.I.
        • et al.
        Intraepidermal nerve fibers are indicators of small-fiber neuropathy in both diabetic and nondiabetic patients.
        Diabetes Care. 2004; 27: 1974-1979
        • Dyck P.J.
        • Lais A.
        • Karnes J.L.
        • et al.
        Fiber loss is primary and multifocal in sural nerves in diabetic polyneuropathy.
        Ann Neurol. 1986; 19: 425-439
        • Cavanagh P.R.
        • Simoneau G.G.
        • Ulbrecht J.S.
        Ulceration, unsteadiness, and uncertainty: the biomechanical consequences of diabetes mellitus.
        J Biomech. 1993; 26: 23-40
        • Katoulis E.C.
        • Ebdon-Parry M.
        • Lanshammar H.
        • et al.
        Gait abnormalities in diabetic neuropathy.
        Diabetes Care. 1997; 20: 1904-1907
        • Vinik A.I.
        • Strotmeyer E.S.
        • Nakave A.A.
        • et al.
        Diabetic neuropathy in older adults.
        Clin Geriatr Med. 2008; 24: 407-435
        • England J.D.
        • Gronseth G.S.
        • Franklin G.
        • et al.
        Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation.
        Neurology. 2005; 64: 199-207
        • Ziegler D.
        • Hidvegi T.
        • Gurieva I.
        • et al.
        Efficacy and safety of lacosamide in painful diabetic neuropathy.
        Diabetes Care. 2010; 33: 839-841
        • Young R.J.
        • Ewing D.J.
        • Clarke B.F.
        Chronic and remitting painful diabetic polyneuropathy. Correlations with clinical features and subsequent changes in neurophysiology.
        Diabetes Care. 1988; 11: 34-40
        • England J.D.
        • Gronseth G.S.
        • Franklin G.
        • et al.
        Practice Parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation.
        Neurology. 2009; 72: 177-184
        • Feldman E.L.
        • Stevens M.J.
        • Thomas P.K.
        • et al.
        A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy.
        Diabetes Care. 1994; 17: 1281-1289
        • Haanpaa M.L.
        • Backonja M.M.
        • Bennett M.I.
        • et al.
        Assessment of neuropathic pain in primary care.
        Am J Med. 2009; 122: S13-S21
        • Boulton A.J.
        • Vinik A.I.
        • Arezzo J.C.
        • et al.
        Diabetic neuropathies: a statement by the American Diabetes Association.
        Diabetes Care. 2005; 28: 956-962
        • Boulton A.J.
        • Gries F.A.
        • Jervell J.A.
        Guidelines for the diagnosis and outpatient management diabetic peripheral neuropathy.
        Diabet Med. 1998; 15: 508-514
        • Vinik A.I.
        • Suwanwalaikorn S.
        • Stansberry K.B.
        • et al.
        Quantitative measurement of cutaneous perception in diabetic neuropathy.
        Muscle Nerve. 1995; 18: 574-584
        • Abbott C.A.
        • Carrington A.L.
        • Ashe H.
        • et al.
        The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort.
        Diabet Med. 2002; 19: 377-384
        • Dyck P.J.
        • Melton III, L.J.
        • O'Brien P.C.
        • et al.
        Approaches to improve epidemiological studies of diabetic neuropathy: insights from the Rochester Diabetic Neuropathy Study.
        Diabetes. 1997; 46: S5-S8
        • Vileikyte L.
        • Peyrot M.
        • Bundy C.
        • et al.
        The development and validation of a neuropathy- and foot ulcer-specific quality of life instrument.
        Diabetes Care. 2003; 26: 2549-2555
        • Cameron N.E.
        • Eaton S.E.
        • Cotter M.A.
        Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy.
        Diabetologia. 2001; 44: 1973-1988
        • Albers J.W.
        • Herman W.H.
        • Pop-Busui R.
        • et al.
        Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study.
        Diabetes Care. 2010; 33: 1090-1096
        • Pop-Busui R.
        • Low P.A.
        • Waberski B.H.
        • et al.
        Effects of prior intensive insulin therapy on cardiac autonomic nervous system function in type 1 diabetes mellitus: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study (DCCT/EDIC).
        Circulation. 2009; 119: 2886-2893
      1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
        Lancet. 1998; 352: 837-853
        • The ADVANCE Collaborative Group
        Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
        N Engl J Med. 2008; 358: 2560-2572
        • Gaede P.
        • Lund-Andersen H.
        • Parving H.H.
        • et al.
        Effect of a multifactorial intervention on mortality in type 2 diabetes.
        N Engl J Med. 2008; 358: 580-591
        • Ziegler D.
        • Sohr C.G.
        • Nourooz-Zadeh J.
        Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy.
        Diabetes Care. 2004; 27: 2178-2183
        • Pittenger G.
        • Vinik A.
        Nerve growth factor and diabetic neuropathy.
        Exp Diabesity Res. 2003; 4: 271-285
        • Vinik A.I.
        Treatment of diabetic polyneuropathy (DPN) with recombinant human nerve growth factor (rhNGF).
        Diabetes. 1999; 48: A54-A55
        • Rivard A.
        • Silver M.
        • Chen D.
        • et al.
        Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF.
        Am J Pathol. 1999; 154: 355-363
        • Tam J.
        • Rosenberg L.
        • Maysinger D.
        INGAP peptide improves nerve function and enhances regeneration in streptozotocin-induced diabetic C57BL/6 mice.
        FASEB J. 2004; 18: 1767-1769
        • Dungan K.M.
        • Buse J.B.
        • Ratner R.E.
        Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP).
        Diabetes Metab Res Rev. 2009; 25: 558-565
        • Bussolino F.
        • Di Renzo M.F.
        • Ziche M.
        • et al.
        Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth.
        J Cell Biol. 1992; 119: 629-641
        • Nakagami H.
        • Kaneda Y.
        • Ogihara T.
        • et al.
        Hepatocyte growth factor as potential cardiovascular therapy.
        Expert Rev Cardiovasc Ther. 2005; 3: 513-519
        • Matsumoto K.
        • Nakamura T.
        Emerging multipotent aspects of hepatocyte growth factor.
        J Biochem. 1996; 119: 591-600
        • Jayasankar V.
        • Woo Y.J.
        • Pirolli T.J.
        • et al.
        Induction of angiogenesis and inhibition of apoptosis by hepatocyte growth factor effectively treats postischemic heart failure.
        J Card Surg. 2005; 20: 93-101
        • Hashimoto N.
        • Yamanaka H.
        • Fukuoka T.
        • et al.
        Expression of HGF and cMet in the peripheral nervous system of adult rats following sciatic nerve injury.
        Neuroreport. 2001; 12: 1403-1407
        • Ajroud-Driss S.
        • Christiansen M.
        • Allen J.A.
        • et al.
        Phase 1/2 open-label dose-escalation study of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with painful diabetic peripheral neuropathy.
        Mol Ther. 2013; 21: 1279-1286
        • Milicevic Z.
        • Newlon P.G.
        • Pittenger G.L.
        • et al.
        Anti-ganglioside GM1 antibody and distal symmetric “diabetic polyneuropathy” with dominant motor features.
        Diabetologia. 1997; 40: 1364-1365
        • Sharma K.
        • Cross J.
        • Farronay O.
        • et al.
        Demyelinating neuropathy in diabetes mellitus.
        Arch Neurol. 2002; 59: 758-765
        • Granberg V.
        • Ejskjaer N.
        • Peakman M.
        • et al.
        Autoantibodies to autonomic nerves associated with cardiac and peripheral autonomic neuropathy.
        Diabetes Care. 2005; 28: 1959-1964
        • Vinik A.I.
        • Anandacoomaraswamy D.
        • Ullal J.
        Antibodies to neuronal structures: innocent bystanders or neurotoxins?.
        Diabetes Care. 2005; 28: 2067-2072
        • Mantyselka P.
        • Ahonen R.
        • Kumpusalo E.
        • et al.
        Variability in prescribing for musculoskeletal pain in Finnish primary health care.
        Pharm World Sci. 2001; 23: 232-236
        • Treede R.D.
        • Jensen T.S.
        • Campbell J.N.
        • et al.
        Neuropathic pain: redefinition and a grading system for clinical and research purposes.
        Neurology. 2008; 70: 1630-1635
        • Jensen M.P.
        • Chodroff M.J.
        • Dworkin R.H.
        The impact of neuropathic pain on health-related quality of life: review and implications.
        Neurology. 2007; 68: 1178-1182
        • Bouhassira D.
        • Lanteri-Minet M.
        • Attal N.
        • et al.
        Prevalence of chronic pain with neuropathic characteristics in the general population.
        Pain. 2008; 136: 380-387
        • Vinik E.
        • Paulson J.
        • Ford-Molvik S.
        • et al.
        German-Translated Norfolk Quality of Life (QOL-DN) identifies the same factors as the English version of the tool and discriminates different levels of neuropathy severity.
        J Diabetes Sci Technol. 2008; 2: 1075-1086
        • Vinik A.I.
        • Casellini C.M.
        Guidelines in the management of diabetic nerve pain: clinical utility of pregabalin.
        Diabetes Metab Syndr Obes. 2013; 6: 57-78
        • Vinik A.
        • Emir B.
        • Raymond C.
        • et al.
        The relationship between pain relief and improvements in patient function/quality of life in patients with painful diabetic peripheral neuropathy or post-herpetic neuralgia treated with pregabalin.
        Clin Ther. 2013; 35: 612-623
        • Castro M.M.
        • Daltro C.
        Sleep patterns and symptoms of anxiety and depression in patients with chronic pain.
        Arq Neuropsiquiatr. 2009; 67: 25-28
        • Gore M.
        • Brandenburg N.A.
        • Dukes E.
        • et al.
        Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep.
        J Pain Symptom Manage. 2005; 30: 374-385
        • Boulanger L.
        • Zhao Y.
        • Foster T.S.
        • et al.
        Impact of comorbid depression or anxiety on patterns of treatment and economic outcomes among patients with diabetic peripheral neuropathic pain.
        Curr Med Res Opin. 2009; 25: 1763-1773
        • Gupta A.
        • Silman J.
        • Ray D.
        • et al.
        The role of psychosocial factors in predicting the onset of chronic widespread pain: results from a prospective population-based study.
        Rheumatology. 2007; 46: 666-671
        • O'Connor A.B.
        Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy.
        Pharmacoeconomics. 2009; 27: 95-112
        • Daousi C.
        • MacFarlane I.A.
        • Woodward A.
        • et al.
        Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes.
        Diabet Med. 2004; 21: 976-982
        • Bennett M.I.
        • Attal N.
        • Backonja M.M.
        • et al.
        Using screening tools to identify neuropathic pain.
        Pain. 2007; 127: 199-203
        • Bastyr E.
        • Zhang D.
        • Bril V.
        • The MBBQ Study Group
        Neuropathy Total symptom Score-6 Questionnaire (NTSS-6) is a valid instrument for assessing the positive symptoms of diabetic peripheral neuropathy (DPN).
        Diabetes. 2002; 51: A199
        • Scholz J.
        • Mannion R.J.
        • Hord D.E.
        • et al.
        A novel tool for the assessment of pain: validation in low back pain.
        PLoS Med. 2009; 6: e1000047
        • Spallone V
        • Morganti R
        • D'Amato C
        • et al.
        Clinical correlates of painful diabetic neuropathy and relationship of neuropathic pain with sensorimotor and autonomic nerve function.
        Eur J Pain. 2011; 15: 153-160
        • Young R.J.
        Structural functional interactions in the natural history of diabetic polyneuropathy: a key to the understanding of neuropathic pain?.
        Diabet Med. 1993; 10: 89S-90S
        • Loeser J.D.
        • Treede R.D.
        The Kyoto protocol of IASP basic pain terminology.
        Pain. 2008; 137: 473-477
        • Bouhassira D.
        • Attal N.
        • Fermanian J.
        • et al.
        Development and validation of the neuropathic pain symptom inventory.
        Pain. 2004; 108: 248-257
        • Bennett M.I.
        • Smith B.H.
        • Torrance N.
        • et al.
        The S-LANSS score for identifying pain of predominantly neuropathic origin: validation for use in clinical and postal research.
        J Pain. 2005; 6: 149-158
        • Krause S.
        • Backonja M.
        Development of a neuropathic pain questionnaire.
        Clin J Pain. 2003; 19: 306-314
        • Bouhassira D.
        • Attal N.
        • Alchaar H.
        • et al.
        Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4).
        Pain. 2005; 114: 29-36
        • Freyhagen R.
        • Baron R.
        • Gockel U.
        Pain detect: a new screening questionnaire to detect neuropathic components in patients with back pain.
        Curr Med Res Opin. 2006; 22: 1911-1920
        • Portenoy R.
        Development and testing of a neuropathic pain screening questionnaire: ID pain.
        Curr Med Res Opin. 2006; 22: 1555-1565
        • Dworkin R.H.
        • Turk D.C.
        • Revicki D.A.
        • et al.
        Development and initial validation of an expanded and revised version of the Short-form McGill Pain Questionnaire (SF-MPQ-2).
        Pain. 2009; 144: 35-42
        • Daut R.L.
        • Cleeland C.S.
        • Flanery R.C.
        Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases.
        Pain. 1983; 17: 197-210
        • Dworkin R.H.
        • Turk D.C.
        • Wyrwich K.W.
        • et al.
        Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations.
        J Pain. 2008; 9: 105-121
        • Cruccu G.
        • Truini A.
        Tools for assessing neuropathic pain.
        PLoS Med. 2009; 6: e1000045
        • Stephenson D.T.
        • Arneric S.P.
        Neuroimaging of pain: advances and future prospects.
        J Pain. 2008; 9: 567-579
        • Chao C.C.
        • Hsieh S.C.
        • Tseng M.T.
        • et al.
        Patterns of contact heat evoked potentials (CHEP) in neuropathy with skin denervation: correlation of CHEP amplitude with intraepidermal nerve fiber density.
        Clin Neurophysiol. 2008; 119: 653-661
        • Atherton D.D.
        • Facer P.
        • Roberts K.M.
        • et al.
        Use of the novel Contact Heat Evoked Potential Stimulator (CHEPS) for the assessment of small fibre neuropathy: correlations with skin flare responses and intra-epidermal nerve fibre counts.
        BMC Neurol. 2007; 7: 21
        • Casanova-Molla J.
        • Grau-Junyent J.M.
        • Morales M.
        • et al.
        On the relationship between nociceptive evoked potentials and intraepidermal nerve fiber density in painful sensory polyneuropathies.
        Pain. 2011; 152: 410-418
        • Chao C.C.
        • Tseng M.T.
        • Lin Y.J.
        • et al.
        Pathophysiology of neuropathic pain in type 2 diabetes: skin denervation and contact heat-evoked potentials.
        Diabetes Care. 2010; 33: 2654-2659
        • Finnerup N.B.
        • Otto M.
        • McQuay H.J.
        • et al.
        Algorithm for neuropathic pain treatment: an evidence based proposal.
        Pain. 2005; 118: 289-305
        • Finnerup N.B.
        • Sindrup S.H.
        • Jensen T.S.
        The evidence for pharmacological treatment of neuropathic pain.
        Pain. 2010; 150: 573-581
        • Dworkin R.H.
        • O'Connor A.B.
        • Backonja M.
        • et al.
        Pharmacologic management of neuropathic pain: evidence-based recommendations.
        Pain. 2007; 132: 237-251
        • Dworkin R.H.
        • O'Connor A.B.
        • Audette J.
        • et al.
        Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.
        Mayo Clin Proc. 2010; 85: S3-S14
        • Edelsberg J.
        • Oster G.
        Summary measures of number needed to treat: how much clinical guidance do they provide in neuropathic pain?.
        Eur J Pain. 2009; 13: 11-16
        • Said G.
        • Bigo A.
        • Ameri A.
        • et al.
        Uncommon early-onset neuropathy in diabetic patients.
        J Neurol. 1998; 245: 61-68
        • Dogrul A.
        • Uzbay I.T.
        Topical clonidine antinociception.
        Pain. 2004; 111: 385-391
        • Tesfaye S.
        • Vileikyte L.
        • Rayman G.
        • et al.
        Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management.
        Diabetes Metab Res Rev. 2011; 27: 629-638
        • Bril V.
        • England J.
        • Franklin G.M.
        • et al.
        Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation.
        Neurology. 2011; 76: 1758-1765
        • Vinik A.
        The approach to the management of the patient with neuropathic pain.
        J Clin Endocrinol Metab. 2010; 95: 4802-4811
        • Ziegler D.
        • Nowak H.
        • Kempler P.
        • et al.
        Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis.
        Diabet Med. 2004; 21: 114-121
        • Ziegler D.
        • Low P.A.
        • Boulton A.J.
        Antioxidant treatment with alpha-lipoic acid in diabetic polyneuropathy: a 4-year randomized double-blind trial (NATHAN 1).
        Diabetologia. 2011; 50: S63
        • Rains C.
        • Bryson H.M.
        Topical capsaicin. A review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy and osteoarthritis.
        Drugs Aging. 1995; 7: 317-328
        • Mason L.
        • Moore R.A.
        • Derry S.
        • et al.
        Systematic review of topical capsaicin for the treatment of chronic pain.
        BMJ. 2004; 328: 991
        • Backonja M.
        • Wallace M.S.
        • Blonsky E.R.
        • et al.
        NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study.
        Lancet Neurol. 2008; 7: 1106-1112
        • Baron R.
        • Mayoral V.
        • Leijon G.
        • et al.
        Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy.
        Curr Med Res Opin. 2009; 25: 1677-1687
        • Jarvis B.
        • Coukell A.J.
        Mexiletine. A review of its therapeutic use in painful diabetic neuropathy.
        Drugs. 1998; 56: 691-707
        • Harati Y.
        • Gooch C.
        • Swenson M.
        • et al.
        Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy.
        Neurology. 1998; 50: 1842-1846
        • Harati Y.
        • Gooch C.
        • Swenson M.
        • et al.
        Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy.
        J Diabetes Complications. 2000; 14: 65-70
        • Nelson K.A.
        • Park K.M.
        • Robinovitz E.
        • et al.
        High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia.
        Neurology. 1997; 48: 1212-1218
        • Sang C.N.
        NMDA-receptor antagonists in neuropathic pain: experimental methods to clinical trials.
        J Pain Symptom Manage. 2000; 19: S21-S25
        • Watson C.P.
        • Moulin D.
        • Watt-Watson J.
        • et al.
        Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy.
        Pain. 2003; 105: 71-78
        • Gilron I.
        • Bailey J.M.
        • Tu D.
        • et al.
        Morphine, gabapentin, or their combination for neuropathic pain.
        N Engl J Med. 2005; 352: 1324-1334
        • Max M.
        • Lynch S.
        • Muir J.
        Effects of desipramine, amitriptyline and fluoxetine on pain in diabetic neuropathy.
        N Engl J Med. 1992; 326: 1250-1256
        • Hardy T.
        • Sachson R.
        • Shen S.
        • et al.
        Does treatment with duloxetine for neuropathic pain impact glycemic control?.
        Diabetes Care. 2007; 30: 21-26
        • Sansone R.A.
        • Sansone L.A.
        Pain, pain, go away: antidepressants and pain management.
        Psychiatry (Edgmont). 2008; 5: 16-19
        • Simpson D.A.
        Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy.
        J Clin Neuromuscul Dis. 2001; 3: 53-62
        • Blom S.
        Trigeminal neuralgia: its treatment with a new anticonvulsant drug (g-32883).
        Lancet. 1962; 21: 839-840
        • LaRoche S.M.
        • Helmers S.L.
        The new antiepileptic drugs: scientific review.
        JAMA. 2004; 291: 605-614
        • Dworkin R.H.
        • Backonja M.
        • Rowbotham M.C.
        • et al.
        Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations.
        Arch Neurol. 2003; 60: 1524-1534
        • Landefeld C.S.
        • Steinman M.A.
        The Neurontin legacy—marketing through misinformation and manipulation.
        N Engl J Med. 2009; 360: 103-106
        • Backonja M.
        • Beydoun A.
        • Edwards K.R.
        • et al.
        Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.
        JAMA. 1998; 280: 1831-1836
        • DeToledo J.C.
        • Toledo C.
        • DeCerce J.
        • et al.
        Changes in body weight with chronic, high-dose gabapentin therapy.
        Ther Drug Monit. 1997; 19: 394-396
        • Lesser H.
        • Sharma U.
        • LaMoreaux L.
        • et al.
        Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial.
        Neurology. 2004; 63: 2104-2110
        • Richter R.W.
        • Portenoy R.
        • Sharma U.
        • et al.
        Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial.
        J Pain. 2005; 6: 253-260
        • Rosenstock J.
        • Tuchman M.
        • LaMoreaux L.
        • et al.
        Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial.
        Pain. 2004; 110: 628-638
        • Freynhagen R.
        • Strojek K.
        • Griesing T.
        • et al.
        Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens.
        Pain. 2005; 115: 254-263
        • Freeman R.
        • Durso-Decruz E.
        • Emir B.
        Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses.
        Diabetes Care. 2008; 31: 1448-1454
        • Kalso E.
        Sodium channel blockers in neuropathic pain.
        Curr Pharm Des. 2005; 11: 3005-3011
        • Dogra S.
        • Beydoun S.
        • Mazzola J.
        • et al.
        Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study.
        Eur J Pain. 2005; 9: 543-554
        • Vinik A.I.
        Diabetic neuropathies: endpoints in clinical research studies.
        in: LeRoith D. Vinik A.I. Contemporary endocrinology: controversies in treating diabetes: clinical and research aspects. Humana Press, Totowa (NJ)2008: 135-156
        • Pittenger G.
        • Mehrabyan A.
        • Simmons K.
        • et al.
        Small fiber neuropathy is associated with the metabolic syndrome.
        Metab Syndr Relat Disord. 2005; 3: 113-121
        • Raskin P.
        • Donofrio P.D.
        • Rosenthal N.R.
        • et al.
        Topiramate vs placebo in painful diabetic neuropathy: analgesic and metabolic effects.
        Neurology. 2004; 63: 865-873
        • Quilici S.
        • Chancellor J.
        • Lothgren M.
        • et al.
        Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain.
        BMC Neurol. 2009; 9: 6-19
        • Burke J.
        • Sanchez R.
        • Joshi A.
        • et al.
        Health care costs in patients with painful diabetic peripheral neuropathy prescribed pregabalin or duloxetine.
        Pain Pract. 2012; 12: 209-218
        • De Salas-Cansado M.
        • Perez C.
        • Saldana M.T.
        • et al.
        An economic evaluation of pregabalin versus usual care in the management of community-treated patients with refractory painful diabetic peripheral neuropathy in primary care settings.
        Prim Care Diabetes. 2012; 6: 303-312
        • Bellows B.K.
        • Dahal A.
        • Jiao T.
        • et al.
        A cost-utility analysis of pregabalin versus duloxetine for the treatment of painful diabetic neuropathy.
        J Pain Palliat Care Pharmacother. 2012; 26: 153-164
        • Gilron I.
        • Bailey J.M.
        • Tu D.
        • et al.
        Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial.
        Lancet. 2009; 374: 1252-1261
        • Thethi T.K.
        • Fonseca V.A.
        • Lavery L.A.
        • et al.
        Metanx in Type 2 Diabetes with Peripheral Neuropathy, A Randomized Trial.
        Am J Med. 2013; 126: 141-149
        • Vinik A.J.
        A medicinal food provides food for thought in managing diabetic neuropathy.
        Am J Med. 2013; 126: 95-96
        • Piovesan E.J.
        • Teive H.G.
        • Kowacs P.A.
        • et al.
        An open study of botulinum-A toxin treatment of trigeminal neuralgia.
        Neurology. 2005; 65: 1306-1308
        • Tsai C.P.
        • Liu C.Y.
        • Lin K.P.
        • et al.
        Efficacy of botulinum toxin type A in the relief of carpal tunnel syndrome: a preliminary experience.
        Clin Drug Investig. 2006; 26: 511-515
        • Pittler M.H.
        • Ernst E.
        Complementary therapies for neuropathic and neuralgic pain: systematic review.
        Clin J Pain. 2008; 24: 731-733
        • Tesfaye S.
        Painful diabetic neuropathy. Aetiology and nonpharmacological treatment.
        in: Veves A. Clinical management of diabetic neuropathy. Humana Press, Totowa (NJ)1998: 369-386
        • Spallone V.
        • Ziegler D.
        • Freeman R.
        • et al.
        Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management.
        Diabetes Metab Res Rev. 2011; 27: 639-653
        • Maser R.E.
        • Mitchell B.D.
        • Vinik A.I.
        • et al.
        The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis.
        Diabetes Care. 2003; 26: 1895-1901
        • Ziegler D.
        • Zentai C.P.
        • Perz S.
        • et al.
        Prediction of mortality using measures of cardiac autonomic dysfunction in the diabetic and nondiabetic population: the MONICA/KORA Augsburg Cohort Study.
        Diabetes Care. 2008; 31: 556-561
        • Lykke J.A.
        • Tarnow L.
        • Parving H.H.
        • et al.
        A combined abnormality in heart rate variation and QT corrected interval is a strong predictor of cardiovascular death in type 1 diabetes.
        Scand J Clin Lab Invest. 2008; 68: 654-659
        • Hage F.G.
        • Iskandrian A.E.
        Cardiovascular imaging in diabetes mellitus.
        J Nucl Cardiol. 2011; 18: 959-965
        • Burgos L.G.
        • Ebert T.J.
        • Assiddao C.
        • et al.
        Increased intraoperative cardiovascular morbidity in diabetics with autonomic neuropathy.
        Anesthesiology. 1989; 70: 591-597
        • Kitamura A.
        • Hoshino T.
        • Kon T.
        • et al.
        Patients with diabetic neuropathy are at risk of a greater intraoperative reduction in core temperature.
        Anesthesiology. 2000; 92: 1311-1318
      2. The definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy.
        J Auton Nerv Syst. 1996; 58: 123-124
        • Low P.A.
        • Walsh J.C.
        • Huang C.Y.
        • et al.
        The sympathetic nervous system in diabetic neuropathy. A clinical and pathological study.
        Brain. 1975; 98: 341-356
        • Gaede P.
        • Vedel P.
        • Parving H.H.
        • et al.
        Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomized study.
        Lancet. 1999; 353: 617-622